Ocular Therapeutix says it's filing a new drug application with the FDA to broaden the indication for its flagship OTX-DB ocular pain drug, now named Dextenza.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1HzMAmb
Cap comentari:
Publica un comentari a l'entrada